WGS Stock Forecast & Price Target

GeneDx Holdings is benefiting from a structural reimbursement shift that moves whole genome sequencing from “not medically necessary” to medically necessary when criteria are met, which should accelerate adoption of the more comprehensive first-line test and reduce outpatient coverage uncertainty. The company’s 1Q26 volumes rose about 34% year over year to 27,488, with genome reaching 45% of WGS/WES volume and 40% of outpatient volume, driving an ASP of about $3,296 even as mix shifted toward lower-priced genomes. It also has multiple growth levers in 2026, including a near-tripling of the sales force to about 160 reps, 30%+ WES/WGS volume growth, and new product and market expansion opportunities that support margin expansion and profitability.

GeneDx Holdings is viewed negatively because management cut its 2026 revenue guide by $65 million, or 12%, to $475-490 million despite still implying +11-15% Y/Y growth, while core exome and genome revenue guidance slowed to 20%+ from +33-35% and volume guidance to 30%+ from +33-35%. The revision was spread across five separate buckets, which raises concern about forecasting quality and execution discipline, and the company’s own 2Q26 guide of $110-112 million on ~30,000 volumes and ~$100 million in exome/genome revenue suggests only modest near-term operating leverage despite ~70% adjusted gross margin. More broadly, the economics of first-line genome coverage appear diluted by a 50% eligibility haircut and only 80% payment realization, making the incremental reimbursement opportunity smaller and less certain than the growth narrative implies.